Case | Sex (f/m) | Age (years) | Smoking (Y\N) | Comorbidity/history | Diagnosis | CT findings | Pathology | BAL | Antibiotics | Therapy (cd) | In-hospital outcome, cause of death |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | F | 62 | Y | Dermato-myositis PMH: Breast cancer | Anti-MDA5 dermato-myositis | OP with architectural distortion | N/A | ng | Augmentin, ceftazidimea | MPSb 1 g CYCc 600 mg/m2 | Death, progressive respiratory failure |
2 | M | 60 | N | UCTD AF, DM, OSAS | UCTD-ILD | OP with architectural distortion | N/A | ng | SDD | MPS 3 g CYC 600 mg/m2 | Survival |
3 | F | 60 | N | AVNRT | Medium-size-artery vasculitis | Diffuse GGO and consolidation | Vasculitis DAH | ng | SDD | MPS 6 g CYC 750 mg/m2 IVIG | Survival |
4 | M | 41 | N | GPA | GPA | Diffuse GGO | Eosinophilic necrotizing granulomatous inflammation | ng | SDD | MPS 3 g Continuous oral CYC 2 mg/kg Plasmapheresis | Survival |
5 | F | 40 | N | Neuro-fibromatosis type 1 RA | ANCA-negative small vessel vasculitis | Diffuse GGO | Vasculitis DAH | ng | SDD | MPS 12 g CYC 750 mg/m2 IVIG Plasmapheresis | Death MOF |
6 | M | 61 | N | None | Methotrexate-induced lung injury | Fibrotic NSIP | N/A | ng | SDD moxifloxacina | MPS 3 g CYC 600 mg/m2 | Survival |
7 | M | 55 | Y | Alcoholism, coronary heart disease | AIP | Diffuse GGO with architectural distorsion | N/A | ng | Augmentin Doxycyclinea | MPS 3 g CYC 500 mg/m2 ECLA | Death Progressive respiratory failure |
8 | M | 44 | Y | SLE | SLE-related ILD | NSIP | N/A | CMV | Ganciclovir SDD | MPS 3 g CYC 600 mg/m2 Plasmapheresis | Survival |
9 | M | 72 | Y | Poliomyelitis PMH: esophageal carcinoma | AIP | Diffuse GGO with architectural distorsion | N/A | ng | Oseltamivir Ceftriaxone Erythromycinea | MPS 3 g CYC 600 mg/m2 | Survival |
10 | M | 52 | N | MCTD PMH: NHL | MCTD-ILD | NSIP | NA | S.aureus | SDD flucloxacillin | MPS 3 g CYC 500 mg/m2 | Survival |
11 | F | 38 | N | SLE | SLE | Diffuse GGO | N/A | ng | Ceftriaxone Azithromycina | MPS 3 g Plasmapheresis CYC 750 mg/m2 | Survival |
12 | F | 68 | Y | PMH: breast cancer and esophageal carcinoma | Unclassified ILD | Unclassified ILD with signs of fibrosis | Fibrosis with organization | ng | SDD | MPS 6 g CYC 600 mg/m2 | Death Progressive respiratory failure |
13 | M | 71 | Y | AF, HPT, RA | AIP | Diffuse GGO, with architectural distorsion | DAD | ng | Ceftriaxone Ciprofloxacina | MPS 3 g CYC 750 mg/m2 | Survival |
14 | M | 54 | Y | DM PMH: Hodgkin lymphoma | EAA | Diffuse GGO | N/A | ng | SDD | MPS 3 g CYC 600 mg/m2 | Death Blocked tracheostomy Progressive respiratory failure |
15 | M | 56 | Y | DM, HPT, COPD | Unclassified ILD | Unclassified ILD with signs of fibrosis | DAD | ng | Augmentin Ciprofloxacina | MPS 3 g CYC 600 mg/m2 | Death |